CAB39 Polyclonal Antibody

Sizes: 60μL, 120μL, 200μL

Catalogue Numbers: E-AB-16615-60, E-AB-16615-120, E-AB-16615-200

Citations, Manuals and MSDS Available upon request.

Abbreviation: CAB39

Target Synonym: Cab39; CAB39; Calcium binding protein 39; Calcium-binding protein 39; CGI 66; CGI-66; CGI66; MO25 alpha; MO25; Mouse protein 25 alpha; Protein Mo25

Research Areas: Cancer, Metabolism, Signal transduction

Conjugation: Unconjugated

Host: Rabbit

Species Reactivity: Human, Mouse

Application: WB, IHC, ELISA

Isotype: IgG

Clonality: Polyclonal

UNIProt ID: Q9Y376

Background: Peutz-Jeghers Syndrome (PJS) is a rare hereditary disease characterized by melanocytic macules of the lips, gastrointestinal hamartomatous polyps and an increased risk for many classes of cancer. The serine/threonine kinase LKB1 (also designated STK11) has been identified as the gene mutated in PJS. LKB1 activity increases upon the binding of a regulatory complex consisting of the STE20-related adaptor-alpha (STRAD alpha) pseudo kinase and the calcium binding protein 39 (MO25 alpha). STRAD and MO25 determine the subcellular localization of LKB1 by initiating its translocation from the nucleus to the cytoplasm, thus regulating the tumor suppressor activity of LKB1. The LKB1/STRAD/MO25 complex acts as an AMP-activated protein kinase kinase (AMPKK).

Concentration: 0.7 mg/mL

Immunogen: Synthetic peptide of human CAB39

Buffer: PBS with 0.05% sodium azide and 50% glycerol, PH7.4

Purification Method: Affinity purification

Dilution: WB 1:500-1:2000, IHC 1:50-1:200

Calculated MW: 40kDa

Storage: -20°C/One year. Avoid freeze / thaw cycles.

Shipping: Ice bag

Research Use Only